Navigation Links
Arena Pharmaceuticals to Present at the Piper Jaffray Fourth Annual Europe Conference
Date:6/18/2009

SAN DIEGO, June 18, 2009 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that the company is scheduled to present at the Piper Jaffray Fourth Annual Europe Conference on June 23, 2009 at 9:30 a.m. British Summer Time (4:30 am Eastern Time, 1:30 a.m. Pacific Time) at the Andaz Hotel in London. Dominic P. Behan, Ph.D., Arena's Senior Vice President and Chief Scientific Officer, is scheduled to provide an overview of the company, including its clinical development and research programs.

A live audio webcast of the presentation will be available under the investor relations section of Arena's website at www.arenapharm.com. A replay of the presentation will be available for 30 days following the event. Please connect to Arena's website several minutes prior to the start of the webcast to ensure adequate time for any software download that may be necessary.

About Arena Pharmaceuticals

Arena is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing oral drugs in four major therapeutic areas: cardiovascular, central nervous system, inflammatory and metabolic diseases. Arena's most advanced drug candidate, lorcaserin, is being investigated in a Phase 3 clinical trial program for weight management. Arena's broad pipeline of novel compounds target G protein-coupled receptors, an important class of validated drug targets, and includes compounds being evaluated independently and with partners, including Merck & Co., Inc., and Ortho-McNeil-Janssen Pharmaceuticals, Inc.

Arena Pharmaceuticals(R) and Arena(R) are registered service marks of the company. "APD" is an abbreviation for Arena Pharmaceuticals Development.

Forward-Looking Statements

Certain statements in this press release are forward-looking statements that involve a number of risks and uncertainties. Such forward-looking statements include statements about Arena's strategy, internal and partnered programs, and ability to develop compounds and commercialize drugs. For such statements, Arena claims the protection of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ materially from Arena's expectations. Factors that could cause actual results to differ materially from the forward-looking statements include, but are not limited to, Arena's ability to obtain additional funds; the timing, success and cost of Arena's lorcaserin program and other of its research and development programs; results of clinical trials or preclinical studies may not be predictive of future results; clinical trials and studies may not proceed at the time or in the manner Arena expects or at all; Arena's ability to partner lorcaserin or other of its compounds or programs; the timing and ability of Arena to receive regulatory approval for its drug candidates; Arena's ability to obtain and defend its patents; and the timing and receipt of payments and fees, if any, from Arena's collaborators. Additional factors that could cause actual results to differ materially from those stated or implied by Arena's forward-looking statements are disclosed in Arena's filings with the Securities and Exchange Commission. These forward-looking statements represent Arena's judgment as of the time of this release. Arena disclaims any intent or obligation to update these forward-looking statements, other than as may be required under applicable law.

    Contacts: Jack Lief
              President and Chief Executive Officer

              Cindy McGee
              Senior Communications Associate

              Arena Pharmaceuticals, Inc.
              858.453.7200, ext. 1479



'/>"/>
SOURCE Arena Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Arena Pharmaceuticals to Receive $100 Million from Deerfield Management
2. New arenavirus discovered as cause of hemorrhagic fever outbreak in South Africa and Zambia
3. Arena Pharmaceuticals to Present at the 34th Annual Deutsche Bank Health Care Conference
4. Arena Pharmaceuticals Announces Positive Lorcaserin Pivotal Phase 3 Obesity Trial Results: Meets All Primary Efficacy and Safety Endpoints
5. Arena Pharmaceuticals to Report Fourth Quarter and Full Year 2008 Financial Results and to Host Conference Call and Webcast on Thursday, March 12, 2009
6. Arena Pharmaceuticals Announces Initiation by Merck of Phase 2 Clinical Trial of Niacin Receptor Agonist
7. Arena Pharmaceuticals to Present at the BIO CEO & Investor Conference
8. Arena Pharmaceuticals to Host Research & Development Day on December 15, 2008
9. Arena Pharmaceuticals Announces Lorcaserin Phase 2b Clinical Trial Results Published in Obesity
10. Arena Pharmaceuticals to Present at the Piper Jaffray 20th Annual Health Care Conference
11. Arena Pharmaceuticals Announces Third Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/21/2017)... CA (PRWEB) , ... January 21, 2017 , ... ... Director of Alumni Relations, Dianne Travis-Teague, the electrifying line-up of events for its ... for alumni, family, friends, and community. “Coming Home 2017” will be held ...
(Date:1/21/2017)... ... 2017 , ... The Nobel Biocare™ dental implant company is ... its creos™ line of bone regenerative products. Specifically, the Nobel Biocare™ ... creos™ allo.gain™ bone graft for a variety of bone reconstruction procedures. In addition ...
(Date:1/20/2017)... Raton, FL (PRWEB) , ... January 20, 2017 , ... ... seaweeds, botanicals and 100 percent pure essential oils, announced the company had a successful ... SC. , The annual ECRM event gives companies that work in the nutritional, sports ...
(Date:1/20/2017)... Boca Raton, FL (PRWEB) , ... January 20, ... ... creating nutritional and wellness products to enhance people’s everyday lives, recently attended the ... major retail buyers. , ATP Science is known for its large range of ...
(Date:1/20/2017)... ... January 20, 2017 , ... Vitamin ... alternative VW+ 002. The drinks have been produced in collaboration with Zlatan Ibrahimovic ... during your workout. , After a successful launch in Sweden last year, the ...
Breaking Medicine News(10 mins):
(Date:1/23/2017)... SAN DIEGO and PALMA, ... Laboratoris Sanifit S.L., a clinical-stage biopharmaceutical ... announced that the first patient has been enrolled ... of lead candidate, SNF472, for the treatment of ... haemodialysis (HD). Most ESRD patients, in ...
(Date:1/22/2017)... and ABU DHABI , Saudi Arabia ... from the US ... Hospital of the Future , at the World Economic ... of the future will be driven by big data and powered by artificial ... the panel of experts that discussed the ,Hospital of the Future, at the ...
(Date:1/21/2017)... 20, 2017 ARMO BioSciences, Inc., a late-stage ... the Company,s lead investigational immuno-oncology drug AM0010 (PEGylated Interleukin-10) ... American Society of Clinical Oncology (ASCO), taking place January ... "AM0010 induces the expansion of ... T cells in the blood and tumors of our ...
Breaking Medicine Technology: